ThermoGenesis EPS misses by $0.27, misses on revenue
ThermoGenesis (THMO): Q3 GAAP EPS of -$0.37 misses by $0.27.Revenue of $2.36M (-41.9% Y/Y) misses by $1.52M.Press Release
Seekingalpha · 11/12 21:13
ThermoGenesis Holdings Q3 EPS $(0.37) Up From $(0.49) YoY, Sales $2.40M Miss $3.88M Estimate
ThermoGenesis Holdings (NASDAQ:THMO) reported quarterly losses of $(0.37) per share. This is a 24.49 percent increase over losses of $(0.49) per share from the same period last year. The company reported quarterly sales
Benzinga · 11/12 21:12
ThermoGenesis Holdings, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 12, 2020 / ThermoGenesis Holdings, Inc.
ACCESSWIRE · 11/12 19:30
ThermoGenesis up 7% on U.S. emergency use extension for COVID-19 antibody test
Nano cap ThermoGenesis ([[THMO]] +7.2%) perks up on a 10x surge in volume in apparent response to the FDA nod extending emergency use authorization for its SARS-CoV-2 IgM/IgG blood test
Seekingalpha · 10/20 17:47
Precigen and Medigus lead Healthcare gainers; Mallinckrodt and GeoVax Labs lead losers
Gainers: Precigen (PGEN) +26%. Medigus (MDGS) +24%. Aclaris Therapeutics (ACRS) +17%. cbdMD (YCBD) +15%. Abeona Therapeutics (ABEO) +12%.Losers: Mallinckrodt (MNK) -18%. GeoVax Labs (GOVX) -13%. AgeX Therapeutics (AGE) -12%. COMPASS Pathways (CMPS) -9%. ThermoGenesis (THMO) -8%.
Seekingalpha · 10/09 15:01
ThermoGenesis to outline product strategy in COVID-19 at LD Micro 500 conference
ThermoGenesis Holdings (THMO) along with its joint venture, ImmuneCyte plans to roll out a comprehensive diagnostic and therapeutic product line to fight COVID-19 pandemic.The multi-pronged strategy will combine diagnostic, therapeutic
Seekingalpha · 09/02 13:07
ThermoGenesis To Roll Out A 'Comprehensive Diagnostic And Therapeutic Product Line' For COVID-19
RANCHO CORDOVA, Calif., Sept 2, 2020 /PRNewswire/ --ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, along with its
Benzinga · 09/02 12:38
Mid-Afternoon Market Update: Nasdaq Surges 100 Points; LMP Automotive Shares Climb Following Q2 Results
Toward the end of trading Monday, the Dow traded down 0.23% to 27866.73 while the NASDAQ rose 0.92% to 11,120.90. The S&P also rose, gaining 0.34% to 3,384.41.
Benzinga · 08/17 18:31
THMO, OSTK, MBOT and UBX among midday movers
Gainers: Comstock Mining (LODE) +128%.RISE Education Cayman (REDU) +52%.IMARA (IMRA) +51%.LMP Automotive (LMPX) +41%.Altisource Asset Management (AAMC) +37%.Lifeway Foods (LWAY) +33%.ClearOne (CLRO) +31%.CureVac (CVAC) +30%.Microbot Medical (MBOT) (OSTK) +22%.Losers: Unity Biotechnology (UBX) -61%.Interpace Biosciences (IDXG) -30%.ThermoGenesis (THMO) -22%.Fujian Blue
Seekingalpha · 08/17 16:43
Mid-Day Market Update: Gold Rises Over 2%; Unity Biotechnology Shares Plummet
Midway through trading Monday, the Dow traded down 0.24% to 27862.87 while the NASDAQ rose 0.69% to 11,095.55. The S&P also rose, gaining 0.29% to 3,382.79.
Benzinga · 08/17 16:27
SRNE, UBX among premarket losers
Unity Biotechnology (UBX) -51% on stumble with lead drug.Interpace Biosciences (IDXG) -19%.Taiwan Liposome (TLC) -16%.ThermoGenesis Holdings (THMO) -14% on Q2 earnings.Midatech Pharma (MTP) -12%.OncoSec Medical (ONCS) -12% after pricing $15M-share offering.Sorrento Therapeutics (SRNE) -11% after Yale's saliva-based Covid-19
Seekingalpha · 08/17 12:11
5 Stocks To Watch For August 17, 2020
Some of the stocks that may grab investor focus today are:
Benzinga · 08/17 08:47
ThermoGenesis Holdings, Inc. (THMO) CEO Chris Xu on Q2 2020 Results - Earnings Call Transcript
ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Q2 2020 Earnings Conference Call August 14, 2020 4:30 P.M.
Seeking Alpha - Transcript · 08/15 01:14
ThermoGenesis misses on revenue
ThermoGenesis (THMO): Q2 GAAP EPS of -$1.02.Revenue of $2.24M (-48.0% Y/Y) misses by $3.56M.Press Release
Seekingalpha · 08/14 20:09
ThermoGenesis Holdings Enters Into Supply Agreement With New EUA Approved COVID-19 Antibody Test Manufacturer; Marketing To Begin On August 17, 2020
RANCHO CORDOVA, Calif., Aug. 13, 2020 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced
Benzinga · 08/13 12:38
Sonnet BioTherapeutics leads healthcare gainers; ThermoGenesis and Edesa Biotech among losers
Seeking Alpha · 07/31 15:05
TAOP, KODK among premarket losers
Seeking Alpha · 07/31 12:16
ThermoGenesis to Join Russell Microcap® Index
PR Newswire · 06/16 13:30
ThermoGenesis to Join Russell Microcap® Index
Benzinga · 06/16 12:33
ThermoGenesis files patent applications for detection of COVID-19 antibodies
Seeking Alpha - Article · 06/11 12:51
Webull provides a variety of real-time THMO stock news. You can receive the latest news about ThermoGenesis Holdings Inc through multiple platforms. This information may help you make smarter investment decisions.
About THMO
ThermoGenesis Holdings, Inc., formerly Cesca Therapeutics Inc., develops, commercializes and markets a range of automated technologies for chimeric antigen receptor (CAR)-T and other cell-based therapies. It offers a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. Its CAR-TXpress platform is its cellular processing platform. It offers cell manufacturing tools and services in the global cell and gene therapy market.